Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06857955 · ClinicalTrials.gov registry record · Phase 2
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
A Phase 2 study of Hypertension, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 380
- Enrollment target
- 20
- Study locations
NCT06857955: Recruiting Phase 2 study of Hypertension, sponsored by Novartis Pharmaceuticals.
NCT06857955 is a Phase 2 study of Hypertension that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 380 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06857955, a Phase 2 study of Hypertension, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 380 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Primary Outcome
Change from baseline at Month 3 in mean 24hr systolic blood pressure (SBP) by ambulatory blood pressure measurement (ABPM)
Conditions Studied
Interventions
- OTHER Saline
- DRUG QCZ484
Study Locations (20)
Florida
- Clinical Research of Brandon LLC - Brandon
- ALL Medical Research LLC - Cooper City
- National Research Institute - Hialeah
- Cen Exel RCA - Hollywood
- East Coast Institute for Research - Jacksonville
- Entrust Clinical Research - Miami
- Inpatient Research Clinical LLC - Miami Lakes
- Inpatient Research Clinical LLC - Miami Lakes
- Suncoast Clinical Research - New Port Richey
California
- NICRs Research Center - Garden Grove
- Valiance Clinical Research - Huntington Park
- Downtown L.A. Research Center Inc - Los Angeles
- Clinical Trials Research Sacramento - Sacramento
- Encompass Clinical Research - Spring Valley
Alabama
- SEC Clinical Research LLC - Andalusia
- UAB St Vincents - Birmingham
- Longwood Research - Huntsville
- The Center for Clinical Trials - Saraland
Arizona
- Elite Clinical Studies - Phoenix
- Synexus Clinical Research US Inc - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2028-04-05 |
| Phase | Phase 2 |
What NCT06857955 shows while recruiting
NCT06857955 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT06857955 names 20 study sites across 4 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06857955 about?
NCT06857955 is a clinical study titled "A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients". The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
What is the current status of trial NCT06857955?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2025-03-26. Estimated completion is 2028-04-05.
What conditions does trial NCT06857955 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT06857955?
The interventions under investigation include: Saline (OTHER), QCZ484 (DRUG).
Who is sponsoring clinical trial NCT06857955?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06857955 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06857955's enrollment target sits among peer trials
380 152nd of 470 higher than 319 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI